Menu
Home
Portfolio
What we do
🔽

EIR Program

Team
Contact
Portfolio

Renue Bio

Renue Lifesciences Pioneering the Future of Cellular Health

Business Unit:
Lifesciences
Company:
Renue
Website:
View Live
Renue Bio
Renue Bio

Overview

Renue Life Sciences is building the world's first scalable platform for intelligent medicines. By advancing AI-native design, precision gene editing, and stem cell programming, we create first-in-class therapeutics that alter the course of age-related and complex diseases

‍

‍

Renue Bio

Focus Areas

Medical text img
Solid text img
tab second img
tab first img
Chronic Diseases

Problem:
80% of adults 65+ live with at least one incurable chronic disease.
Need:
‍Go beyond symptom management to restore cellular health.
Solution:
‍AI-guided reprogramming therapeutics that reverse or halt disease at its biological root.

Slow, Costly Discovery

Problem:
Drug development takes 10–15 years and over $2.6B with 90% failure rates.
Need:
‍Faster, smarter ways to design adaptive therapies.
Solution:
‍AI-native platform accelerating discovery and precision design of next-gen medicines.

Loss of Regeneration

Problem:
Aging and complex diseases damage cells the body can’t repair.
Need:
‍Safe, targeted rejuvenation of tissues and organs.
Solution:
‍Partial cellular reprogramming to restore and renew function without altering identity.

Key Advantages

‍

Partial reprogramming: Ethical and precise rejuvenation of cells without converting them into stem cells.

Ex vivo applications: Targeting CAR-T cells, engineered NK cells, genetic disorders, IVF, and blood transfusions.

In vivo applications: Rejuvenation of neurons, blood, brain barriers, cosmetics, and skincare.

‍

Explore nCode Biosciences

Other Portfolio Companies

Socratic AI
Socratic AI
Socratic AI
Noki
Noki
Noki